Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy Life Science Investing
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause Life Science Investing
PainReform's LayerBio's Drop-Less OcuRing-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies Life Science Investing
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress Life Science Investing
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones Life Science Investing
